Capital Allocation

EQT appoints M&A mastermind Gustav Segerberg as CFO, signaling a doubling-down on its aggressive growth strategy. What does this mean for its future?

Ottawa unveils a multi-billion dollar plan to transform Canada from an AI research hub into an economic leader, focusing on adoption, sovereignty, and ethics.

As Canada prepares for Pride Season, a new federal funding announcement for security highlights a stark reality: celebration now requires fortification.

Fast Loan UK's new automated debt system promises a leap in efficiency. But as human oversight shrinks, it poses a critical test of regulatory and ethical limits.

AM Best affirms Victoria Insurance's 'Good' rating despite a shrinking footprint, revealing a high-stakes balancing act between a fortress balance sheet and immense market risks.

Market research shows doctors are eager to prescribe Moleculin's new AML drug, Annamycin. It offers hope where there is none, but can the company survive to deliver it?

Amid a regional healthcare crisis, 475 nurses at BMC South plan to picket, citing unsafe staffing and a 'bullying' contract offer from management.

As titans clash for the World Cup betting market, The Sports Geek unveils a new playbook focusing on data, niche audiences, and the staggering cost of fandom.

Ninety percent of firms have increased AI marketing investment, yet a new report reveals only 12% can prove it works. This is the story of a growing crisis.

As Royalty Pharma prepares for a key investor conference, we explore the powerful, low-profile business model that funds blockbuster drugs and shapes innovation.

Facing dire financial warnings, Cosmos Health plans to sell its own facilities to fund a comeback. Is it a stroke of genius or a desperate final gambit?

May's headline job growth masks a troubling reality. New data from Revelio Labs reveals a deepening divide between sectors and a drop in new-hire pay.

With record device sales providing a solid financial base, RenovoRx nears a critical milestone in its high-stakes Phase III trial for a new pancreatic cancer therapy.

With its first product launch, Daré Bioscience enters a new commercial era. But can a single probiotic launch secure the future of its ambitious pipeline?

After years of losses, Wisconsin-based Orion Energy Systems reports a stunning financial recovery. But can its new CEO sustain this momentum in the volatile green-tech market?

Jade Biosciences secures a massive $150M offering to fuel its promising drug pipeline, but the deal's pricing reveals the intense pressures of the biotech market.

The 2026 Federal Budget is rewriting the rules of property investment, pushing capital away from old hotspots and creating a new strategic battleground.

While high oil prices fail to boost rig counts, PHX Energy is doubling down on high-tech drilling tools, a calculated gamble that efficiency, not volume, is king.

ZTR's 10% distribution increase offers a tempting yield, but savvy investors must look beyond the headline rate to the fund's strategy and mechanics.

CrowdStrike reports record earnings and a stock split, but its true story lies in deep AI pacts with OpenAI. Is it enough to secure the AI frontier?